| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proliferating Cell Nuclear Antigen | 17 | 2016 | 31 | 2.760 |
Why?
|
| DNA Repair | 12 | 2016 | 57 | 1.790 |
Why?
|
| DNA Replication | 9 | 2020 | 34 | 1.410 |
Why?
|
| DNA Repair-Deficiency Disorders | 3 | 2016 | 3 | 1.050 |
Why?
|
| Mutation, Missense | 3 | 2016 | 51 | 1.030 |
Why?
|
| Glaucoma | 3 | 2017 | 22 | 0.950 |
Why?
|
| DNA-Directed DNA Polymerase | 8 | 2011 | 13 | 0.920 |
Why?
|
| Trabeculectomy | 2 | 2019 | 3 | 0.700 |
Why?
|
| DNA Damage | 12 | 2021 | 93 | 0.630 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2020 | 43 | 0.620 |
Why?
|
| Ubiquitin | 6 | 2010 | 18 | 0.610 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2016 | 27 | 0.610 |
Why?
|
| Cell Cycle Proteins | 6 | 2018 | 56 | 0.590 |
Why?
|
| Saccharomyces cerevisiae | 5 | 2006 | 19 | 0.540 |
Why?
|
| Ophthalmology | 1 | 2017 | 7 | 0.540 |
Why?
|
| Mutant Proteins | 2 | 2014 | 14 | 0.530 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 14 | 0.520 |
Why?
|
| Educational Measurement | 1 | 2017 | 119 | 0.510 |
Why?
|
| Glaucoma, Open-Angle | 5 | 2019 | 22 | 0.510 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 130 | 0.500 |
Why?
|
| DNA-Binding Proteins | 4 | 2018 | 142 | 0.480 |
Why?
|
| Repressor Proteins | 1 | 2015 | 50 | 0.460 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 34 | 0.450 |
Why?
|
| Chromatin | 5 | 2011 | 26 | 0.440 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 83 | 0.440 |
Why?
|
| Clinical Competence | 1 | 2017 | 338 | 0.440 |
Why?
|
| Patient Care Team | 1 | 2015 | 123 | 0.430 |
Why?
|
| Humans | 42 | 2021 | 32798 | 0.430 |
Why?
|
| Internship and Residency | 1 | 2017 | 324 | 0.410 |
Why?
|
| Cell Cycle | 6 | 2008 | 74 | 0.400 |
Why?
|
| Schizosaccharomyces | 2 | 2010 | 5 | 0.390 |
Why?
|
| Radiation Tolerance | 2 | 2010 | 24 | 0.380 |
Why?
|
| Antibody Formation | 3 | 2021 | 47 | 0.380 |
Why?
|
| Fibroblasts | 4 | 2019 | 114 | 0.370 |
Why?
|
| Chromosomal Instability | 3 | 2020 | 5 | 0.370 |
Why?
|
| Needs Assessment | 1 | 2012 | 75 | 0.360 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2019 | 15 | 0.350 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 80 | 0.350 |
Why?
|
| Immunization, Secondary | 2 | 2021 | 11 | 0.340 |
Why?
|
| Intraocular Pressure | 5 | 2019 | 41 | 0.340 |
Why?
|
| Cell Nucleus | 2 | 2009 | 105 | 0.320 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 103 | 0.300 |
Why?
|
| Medical Records | 2 | 2009 | 77 | 0.290 |
Why?
|
| Multiprotein Complexes | 2 | 2018 | 19 | 0.270 |
Why?
|
| Family | 1 | 2007 | 115 | 0.260 |
Why?
|
| Genomic Instability | 3 | 2020 | 6 | 0.260 |
Why?
|
| Xenopus Proteins | 1 | 2006 | 1 | 0.250 |
Why?
|
| Mutation | 8 | 2020 | 493 | 0.250 |
Why?
|
| Female | 21 | 2021 | 20261 | 0.250 |
Why?
|
| DNA Breaks | 1 | 2005 | 2 | 0.230 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 21 | 0.220 |
Why?
|
| DNA | 4 | 2018 | 218 | 0.210 |
Why?
|
| Mitosis | 2 | 2020 | 24 | 0.200 |
Why?
|
| Adolescent | 8 | 2021 | 3638 | 0.200 |
Why?
|
| Cell Line, Transformed | 2 | 2015 | 18 | 0.200 |
Why?
|
| Male | 16 | 2021 | 19641 | 0.190 |
Why?
|
| Animals | 12 | 2020 | 7569 | 0.190 |
Why?
|
| Models, Biological | 4 | 2020 | 392 | 0.190 |
Why?
|
| Protein Binding | 4 | 2016 | 200 | 0.190 |
Why?
|
| Young Adult | 6 | 2021 | 2730 | 0.190 |
Why?
|
| Histones | 4 | 2019 | 53 | 0.180 |
Why?
|
| Middle Aged | 12 | 2021 | 12125 | 0.180 |
Why?
|
| Ultraviolet Rays | 3 | 2011 | 48 | 0.180 |
Why?
|
| Aldehydes | 1 | 2021 | 4 | 0.170 |
Why?
|
| Immunization Schedule | 1 | 2021 | 26 | 0.170 |
Why?
|
| Carcinogens, Environmental | 1 | 2020 | 2 | 0.170 |
Why?
|
| Aluminum | 1 | 2020 | 4 | 0.170 |
Why?
|
| Cell Line | 8 | 2019 | 433 | 0.170 |
Why?
|
| Centrosome | 1 | 2020 | 2 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 39 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 13 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 8 | 0.170 |
Why?
|
| Ubiquitination | 3 | 2016 | 16 | 0.170 |
Why?
|
| Binding Sites | 3 | 2016 | 129 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 9 | 0.160 |
Why?
|
| Cytogenetic Analysis | 1 | 2019 | 17 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 129 | 0.160 |
Why?
|
| Eye Infections, Bacterial | 1 | 2019 | 5 | 0.150 |
Why?
|
| X Chromosome Inactivation | 1 | 2019 | 6 | 0.150 |
Why?
|
| Endophthalmitis | 1 | 2019 | 8 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 41 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 10 | 0.150 |
Why?
|
| Aneuploidy | 1 | 2018 | 11 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 25 | 0.150 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 300 | 0.140 |
Why?
|
| Optic Disk | 3 | 2007 | 11 | 0.140 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 726 | 0.140 |
Why?
|
| Zinc Fingers | 2 | 2016 | 9 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2019 | 144 | 0.140 |
Why?
|
| Adult | 8 | 2021 | 9560 | 0.130 |
Why?
|
| Mice | 6 | 2020 | 2511 | 0.130 |
Why?
|
| DNA Polymerase III | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cell Fusion | 1 | 2016 | 4 | 0.130 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2016 | 8 | 0.130 |
Why?
|
| Cytoplasm | 1 | 2016 | 28 | 0.130 |
Why?
|
| Apoptosis | 1 | 2018 | 362 | 0.130 |
Why?
|
| Aged | 7 | 2021 | 10538 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4032 | 0.130 |
Why?
|
| Retinal Degeneration | 1 | 2016 | 22 | 0.130 |
Why?
|
| Protein-Serine-Threonine Kinases | 2 | 2020 | 49 | 0.120 |
Why?
|
| Genetic Speciation | 1 | 2016 | 2 | 0.120 |
Why?
|
| Hybridization, Genetic | 1 | 2016 | 3 | 0.120 |
Why?
|
| Protein Engineering | 1 | 2016 | 19 | 0.120 |
Why?
|
| Retina | 1 | 2016 | 84 | 0.120 |
Why?
|
| Infertility | 1 | 2016 | 14 | 0.120 |
Why?
|
| Institutional Management Teams | 1 | 2015 | 2 | 0.120 |
Why?
|
| New Zealand | 1 | 2015 | 9 | 0.120 |
Why?
|
| Health Care Coalitions | 1 | 2015 | 6 | 0.120 |
Why?
|
| Australia | 1 | 2015 | 72 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 767 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2006 | 17 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2010 | 104 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 754 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2019 | 828 | 0.100 |
Why?
|
| Rosaceae | 1 | 2013 | 1 | 0.100 |
Why?
|
| Schizosaccharomyces pombe Proteins | 2 | 2010 | 4 | 0.100 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2013 | 14 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2016 | 96 | 0.100 |
Why?
|
| Indonesia | 1 | 2012 | 8 | 0.090 |
Why?
|
| Tonometry, Ocular | 1 | 2012 | 11 | 0.090 |
Why?
|
| Tasmania | 2 | 2009 | 4 | 0.090 |
Why?
|
| DNA Helicases | 1 | 2011 | 4 | 0.090 |
Why?
|
| Blotting, Western | 3 | 2011 | 287 | 0.080 |
Why?
|
| Incidence | 2 | 2019 | 1238 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2021 | 195 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 789 | 0.080 |
Why?
|
| Replication Protein A | 1 | 2009 | 1 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 76 | 0.080 |
Why?
|
| Microscopy | 1 | 2009 | 26 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 69 | 0.080 |
Why?
|
| Prevalence | 1 | 2012 | 1002 | 0.080 |
Why?
|
| Migraine Disorders | 1 | 2009 | 69 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 42 | 0.070 |
Why?
|
| Nucleic Acid Conformation | 1 | 2008 | 46 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 599 | 0.070 |
Why?
|
| Twins, Dizygotic | 1 | 2007 | 8 | 0.070 |
Why?
|
| Twins, Monozygotic | 1 | 2007 | 15 | 0.070 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2018 | 16 | 0.070 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2007 | 47 | 0.070 |
Why?
|
| Alleles | 2 | 2019 | 253 | 0.060 |
Why?
|
| Recombination, Genetic | 2 | 2016 | 23 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 22 | 0.060 |
Why?
|
| Ubiquitins | 1 | 2006 | 2 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 8 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 79 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2005 | 40 | 0.060 |
Why?
|
| Cisplatin | 1 | 2005 | 81 | 0.060 |
Why?
|
| G2 Phase | 2 | 2020 | 17 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2005 | 83 | 0.050 |
Why?
|
| Sepharose | 1 | 2004 | 6 | 0.050 |
Why?
|
| Nickel | 1 | 2004 | 2 | 0.050 |
Why?
|
| Chromatography, Gel | 1 | 2004 | 9 | 0.050 |
Why?
|
| Epitopes | 1 | 2004 | 24 | 0.050 |
Why?
|
| Vision Disorders | 2 | 2019 | 26 | 0.050 |
Why?
|
| Point Mutation | 2 | 2019 | 28 | 0.050 |
Why?
|
| Chromatin Assembly Factor-1 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 82 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 94 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 107 | 0.050 |
Why?
|
| Fungal Proteins | 1 | 2003 | 9 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 13 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 71 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2009 | 788 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 70 | 0.050 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 20 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2003 | 136 | 0.050 |
Why?
|
| Nucleosomes | 1 | 2002 | 4 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3438 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2002 | 94 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 10 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2021 | 5 | 0.040 |
Why?
|
| DNA Adducts | 1 | 2021 | 12 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2021 | 7 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 23 | 0.040 |
Why?
|
| Metformin | 1 | 2021 | 23 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2020 | 12 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 16 | 0.040 |
Why?
|
| South Africa | 1 | 2020 | 14 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 20 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 14 | 0.040 |
Why?
|
| Esophagus | 1 | 2021 | 25 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 73 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 17 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 2020 | 3 | 0.040 |
Why?
|
| Phthalazines | 1 | 2020 | 4 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2020 | 36 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 11 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2020 | 59 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 55 | 0.040 |
Why?
|
| Microtubules | 1 | 2020 | 22 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 169 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 52 | 0.040 |
Why?
|
| Pedigree | 2 | 2014 | 140 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 89 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2020 | 120 | 0.040 |
Why?
|
| Histological Techniques | 1 | 2020 | 8 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2014 | 186 | 0.040 |
Why?
|
| Karyotyping | 1 | 2020 | 28 | 0.040 |
Why?
|
| RNA, Guide | 1 | 2019 | 3 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 11 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 97 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 31 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2019 | 38 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 67 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 78 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 525 | 0.040 |
Why?
|
| Vaccination | 1 | 2020 | 146 | 0.040 |
Why?
|
| Exfoliation Syndrome | 1 | 2019 | 2 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 134 | 0.040 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2019 | 3 | 0.040 |
Why?
|
| Victoria | 1 | 2019 | 24 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 622 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 15 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 45 | 0.040 |
Why?
|
| Exons | 1 | 2019 | 52 | 0.040 |
Why?
|
| Glycolysis | 1 | 2018 | 20 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 638 | 0.040 |
Why?
|
| Gene Expression | 1 | 2020 | 334 | 0.040 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2018 | 5 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 316 | 0.040 |
Why?
|
| DNA, Single-Stranded | 1 | 2018 | 13 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2019 | 76 | 0.040 |
Why?
|
| Bacteria | 1 | 2019 | 55 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 160 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 532 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 74 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 2 | 2011 | 12 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2011 | 820 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2019 | 151 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2010 | 282 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 352 | 0.030 |
Why?
|
| Integrases | 1 | 2016 | 2 | 0.030 |
Why?
|
| X Chromosome | 1 | 2016 | 27 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 3701 | 0.030 |
Why?
|
| Y Chromosome | 1 | 2016 | 43 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 332 | 0.030 |
Why?
|
| Chromosome Pairing | 1 | 2016 | 1 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2016 | 13 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 258 | 0.030 |
Why?
|
| Xeroderma Pigmentosum | 2 | 2005 | 2 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 3974 | 0.030 |
Why?
|
| Meiosis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 2183 | 0.030 |
Why?
|
| Regeneration | 1 | 2016 | 170 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 686 | 0.030 |
Why?
|
| Child | 2 | 2014 | 2478 | 0.030 |
Why?
|
| Dwarfism | 1 | 2014 | 5 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Aging, Premature | 1 | 2014 | 4 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2014 | 18 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 2014 | 12 | 0.030 |
Why?
|
| Photosensitivity Disorders | 1 | 2014 | 12 | 0.030 |
Why?
|
| Telangiectasis | 1 | 2014 | 5 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 58 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 40 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 71 | 0.030 |
Why?
|
| Syndrome | 1 | 2014 | 74 | 0.030 |
Why?
|
| Hearing Loss | 1 | 2014 | 26 | 0.030 |
Why?
|
| Cell Survival | 2 | 2005 | 280 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 247 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2009 | 1572 | 0.030 |
Why?
|
| Patch Tests | 1 | 2013 | 8 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1012 | 0.020 |
Why?
|
| Neoplasms | 1 | 2019 | 761 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Methylation | 1 | 2011 | 5 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 16 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 15 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2011 | 12 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 43 | 0.020 |
Why?
|
| Hela Cells | 1 | 2011 | 80 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 77 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 255 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 226 | 0.020 |
Why?
|
| Mutagens | 1 | 2010 | 3 | 0.020 |
Why?
|
| Nuclear Localization Signals | 1 | 2010 | 4 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 60 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 72 | 0.020 |
Why?
|
| Methyl Methanesulfonate | 1 | 2008 | 4 | 0.020 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2008 | 1 | 0.020 |
Why?
|
| Anthraquinones | 1 | 2008 | 5 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 475 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 576 | 0.020 |
Why?
|
| Visual Fields | 1 | 2006 | 27 | 0.020 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Rad51 Recombinase | 1 | 2006 | 2 | 0.020 |
Why?
|
| DNA, Fungal | 1 | 2006 | 3 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2006 | 23 | 0.020 |
Why?
|
| Optic Nerve Diseases | 1 | 2006 | 19 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2005 | 9 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 24 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2005 | 20 | 0.020 |
Why?
|
| DNA Polymerase beta | 1 | 2005 | 1 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2005 | 2 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2005 | 85 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 91 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 14 | 0.010 |
Why?
|
| Lod Score | 1 | 2005 | 73 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2005 | 36 | 0.010 |
Why?
|
| Eye Proteins | 1 | 2005 | 36 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 94 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 184 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 731 | 0.010 |
Why?
|
| Genes, cdc | 1 | 2003 | 5 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 15 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 881 | 0.010 |
Why?
|